Blog - INTERNET MÉDICA

Esclerose Múltipla: Artigos de Revisão Online (Multiple Sclerosis: Review)

Por Paulo Leite 26/05/2019

■ European and American guidelines or multiple sclerosis treatment

Angelo Ghezzi

Neurol Ther. 2018 Dec; 7(2): 189–194

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283786/

■ Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis

Marques, Vanessa Daccach et al.

Arq. Neuro-Psiquiatr., Aug 2018, vol.76, no.8, p.539-55

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018000800539&lng=pt&nrm=iso&tlng=en

■ A systematic review and meta-analysis of the brief cognitive assessment for multiple sclerosis (BICAMS)

Freya Corfield, Dawn Langdon

Neurol Ther. 2018 Dec; 7(2): 287–306

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283796/

■ Recommendations for cognitive screening and management in multiple sclerosis care

Rosalind Kalb, Meghan Beier, Ralph HB Benedict, et al

Mult Scler. 2018 Nov; 24(13): 1665–1680.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238181/

■ Vitamin D and multiple sclerosis: a comprehensive review

Martina B. Sintzel, Mark Rametta, Anthony T. Reder

Neurol Ther. 2018 Jun; 7(1): 59–85

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990512/

■ Practical evidence-based recommendations for patients with multiple sclerosis who want to have children

Yara Dadalti Fragoso, Tarso Adoni, Joseph B. Bidin Brooks et al

Neurol Ther. 2018 Dec; 7(2): 207–232

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283793/

■ Basal cortisol levels and the relationship with clinical symptoms in multiple sclerosis: a systematic review

Pereira, Gabriela Magalhães et al.

Arq. Neuro-Psiquiatr., Sept 2018, vol.76, no.9, p.622-634

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018000900622

■ Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study

Laisheng Cai, Jingwei Huang

Neuropsychiatr Dis Treat. 2018; 14: 2241–2254

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126505/

■ Repetitive transcranial magnetic stimulation, cognition, and multiple sclerosis: an overview

Grigorios Nasios, Lambros Messinis, Efthimios Dardiotis, Panagiotis Papathanasopoulos

Behav Neurol. 2018; 2018: 8584653

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822759/

■ Monitoring progressive multiple sclerosis with novel imaging techniques

Maria Petracca, Monica Margoni, Giulia Bommarito, Matilde Inglese

Neurol Ther. 2018 Dec; 7(2): 265–285

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283788/

■ Decision-making in multiple sclerosis patients: a systematic review

M Neuhaus, P Calabrese, J Annoni

Multiple Sclerosis International 2018, Article ID 7835952, 9 pages

https://www.hindawi.com/journals/msi/2018/7835952/

■ MRI in the assessment and monitoring of multiple sclerosis: an update on best practice

Ulrike W. Kaunzner, Susan A. Gauthier

Ther Adv Neurol Disord. 2017 Jun; 10(6): 247–261

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453402/

■ Current and emerging therapies in multiple sclerosis: implications for the radiologist, Part 1 – mechanisms, efficacy, and safetyurveillance for treatment complications and disease progression

McNamara, G. Sugrue, B. Murray and P.J. MacMahon

American Journal of Neuroradiology September 2017, vol 38 (9): 1664-1671

http://www.ajnr.org/content/ajnr/early/2017/04/13/ajnr.A5147.full.pdf

■ Current and emerging therapies in multiple sclerosis: implications for the radiologist, Part 2 – surveillance for treatment complications and disease progression

McNamara, G. Sugrue, B. Murray and P.J. MacMahon

American Journal of Neuroradiology September 2017, vol 38 (9): 1672-1680

http://www.ajnr.org/content/ajnr/38/9/1672.full.pdf

■ Multidisciplinary rehabilitation is efficacious and induces neural plasticity in multiple sclerosis even when complicated by progressive multifocal leuckoencephalopathy

Elisabetta Groppo, Francesca Baglio, Davide Cattaneo et al

Front Neurol. 2017; 8: 491

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610687/

■ Disease-modifying treatments for multiple sclerosis – a review of approved medications

Ø Torkildsen, K-M Myhr, L Bø

Eur J Neurol. 2016 Jan; 23(Suppl 1): 18–27

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670697/

■ Treatment strategies for multiple sclerosis: When to star, when to change, when to stop?

Alberto Gajofatto, Maria Donata Benedetti

World J Clin Cases. 2015 Jul 16; 3(7): 545–555.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517331/

■ The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review

Ruth Ann Marrie, Stephen Reingold, Jeffrey Cohen et al

Mult Scler. 2015 Mar; 21(3): 305–317

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429164/

■ A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview

Ruth Ann Marrie, Jeffrey Cohen, Olaf Stuve et al

Mult Scler. 2015 Mar; 21(3): 263–281

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361468/

■ Defining the clinical course of multiple sclerosis: The 2013 revisions

Fred D. Lublin, Stephen C. Reingold, Jeffrey A. Cohen et al

Neurology. 2014 Jul 15; 83(3): 278–286

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117366/

■ Multiple sclerosis in children: an update on clinical diagnosis

Amy Waldman, Prof Angelo Ghezzi, Amit Bar-Or et al

Lancet Neurol. 2014 Sep; 13(9): 936–948

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443918/

■ Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Estratificação de Risco Cardiovascular

Novo endereço:

Consultório: Rua Padre Rolim 815/sala 815

Tel: 33245518 (Consulta Particular/Unimed)

– Centro Médico Unimed BH/Contagem/Pedro I

Belo Horizonte/MG/Brasil

CRMMG: 7026

Email: pfleite1873@gmail.com

Atrofia Muscular Espinhal Online (Spinal Muscular Atrophy)

Por Paulo Leite 25/05/2019

¨A atrofia muscular espinhal (AME) é uma doença neurodegenerativa com herança genética autossômica recessiva. A doença é causada por uma deleção ou mutação homozigótica do gene 1 de sobrevivência do motoneurônio (SMN₁), localizado na região telomérica do cromossomo 5q13, sendo que o número de cópias de um gene semelhante a ele (SMN₂), localizado na região centromérica, é o principal determinante da gravidade da doença. A classificação clínica da AME é dada pela idade de início e máxima função motora adquirida, sendo então dividida em: 1) severa (tipo I, AME aguda ou doença de Werdnig-Hoffmann); 2) intermediária (tipo II ou AME crônica); 3) branda (tipo III, AME juvenil ou doença de Kugelberg-Welander); e 4) tipo IV (AME adulta). Outros autoresclassificam a AME em apenas três categorias: severa, intermediária e branda. A AME é uma desordem de difícil diagnóstico e de tratamento ainda incerto. Seu diagnóstico é dado pela evidência, tanto eletrofisiológica como histológica, de desnervação do músculo³. Para confirmar o diagnóstico, é feita atualmente uma análise molecular, que é dada pela detecção da ausência do éxon 7 do gene SMN_1.Por ser uma doença neurodegenerativa progressiva, o paciente acometido pela AME necessita de vários cuidados especiais, que podem estacionar o progresso da doença e prolongar a vida do mesmo. Infelizmente, nenhum tratamento farmacológico para a AME encontra-se hoje disponível. Algumas drogas que estão sendo testadas no tratamento de pacientes com AME têm como alvo terapêutico o gene SMN₂.¨

■ Monitoring kidney dysfunction in Kugelber-Welander syndrome

M West, M M Nash, L Rapi et al

Am J Case Rep 2019, vol 20: 331-446

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459160/

■ Treatment algorithm or infants diagnosed with spinal muscular atrophy through newborn screening

Jacqueline Glascock, Jacinda Sampson, Amanda Haidet-Phillips et al

J Neuromuscul Dis. 2018; 5(2): 145–158

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004919/

■ Emerging therapies and challenges in spinal muscular atrophy

Michelle A. Farrar, Susanna B. Park, Steve Vucic et al

Ann Neurol. 2017 Mar; 81(3): 355–368

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396275/